DelfaGLP-1 Atlas

Lead sponsor

University of Palermo

5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

5

Trials led

0

Active

764

Total enrollment

1

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 4
3
Not applicable
2

Trials by status

Completed
5

Trials led

Liraglutide and Cardio-Metabolic Risk Markers—not applicableCompleted300
Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes MellitusHbA1c ≥6.5%not applicableCompleted212
Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients—Ph 4Completed100
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables—Ph 4Completed92
Exenatide Once Weekly, Cardiovascular Risk and Type-2 DiabetesBMI ≥25Ph 4Completed60